1
Enquiry period
with 27.11.2025 09:22
to 08.12.2025 08:30
10 days left
2
Bidding period
with 08.12.2025 08:30
to 26.12.2025 08:30
3
Auction

4
Evaluation
5
Bids have been evaluated
Status Active
Estimated value without VAT 5 128,80 MDL
Period of clarifications: 27 Nov 2025, 9:22 - 8 Dec 2025, 8:30
Submission of proposals: 8 Dec 2025, 8:30 - 26 Dec 2025, 8:30
Auction start date: will not be used

Supplier technical support:

(+373) 79999801


This procedure is carried out without auction. Your offer is final and must contain the entire list of required documents.

Specificații pentru investigații clinice generale
Information about customer
Fiscal code/IDNO
Address
3505, MOLDOVA, Orhei, mun.Orhei, str. C.Negruzzi 85
Web site
---
The contact person
Full name
IMSP Spitalul raional Orhei
Contact phone
078830509
Purchase data
Date created
27 Nov 2025, 9:11
Date modified
27 Nov 2025, 9:22
Estimated value (without VAT)
5 128,80 MDL
Achizitii.md ID
21514893
Type of procedure
Open tender
Award criteria
The lowest price
Delivery address
3505, MOLDOVA, Orhei, mun.Orhei, str. C.Negruzzi 85
Contract period
1 Jan 2026 02:00 - 31 Dec 2026 02:00
List of positions
1)
Title
Azur-Eozină Romanovschi soluție 1000 ml CPV: 33600000-6 - Pharmaceutical products
Quantity: 2000.0
Unit of measurement: Centimetru cub; mililitru
2)
Title
Ulei de imersie de la 50-100 ml, fl. Cu pipeta CPV: 33600000-6 - Pharmaceutical products
Quantity: 600.0
Unit of measurement: Centimetru cub; mililitru
3)
Title
Toliclon Anti-A CPV: 33600000-6 - Pharmaceutical products
Quantity: 6.0
Unit of measurement: Bucata
4)
Title
Toliclon Anti-B CPV: 33600000-6 - Pharmaceutical products
Quantity: 6.0
Unit of measurement: Bucata
5)
Title
Toliclon Anti-AB CPV: 33600000-6 - Pharmaceutical products
Quantity: 2.0
Unit of measurement: Bucata
6)
Title
Toliclon Anti-D IgM+IgG CPV: 33600000-6 - Pharmaceutical products
Quantity: 20.0
Unit of measurement: Bucata
Advertising
Documents of the procurement procedure
Question's name
Question
At the moment there are no questions to lot
Clarifications